Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F-C Bidard

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
ESMO Open|June 4, 2026
Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trialC Blaye, F-C Bidard, L Hue, et al.
ESMO Open|May 22, 2021
HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancerL Cabel, C Bonneau, A Bernard-Tessier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 14, 2025
Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trialK L Jhaveri, P Neven, M L Casalnuovo, et al.
Oncogene|January 7, 2023
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access programD Bello Roufai, A Gonçalves, T De La Motte Rouge, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2025
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancerA Mamann, Y Pradat, F C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2025
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapyE L Mayer, F-C Bidard, Y H Park, et al.
ESMO Open|April 10, 2026
Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trialG Curigliano, J O'Shaughnessy, F-C Bidard, et al.
ESMO Open|November 26, 2025
PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohortF Cherifi, L Cabel, C Bousrih, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumabJ-Y Pierga, F-C Bidard, A Autret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2022
Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancerK Van Baelen, T Geukens, M Maetens, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
ESMO Open|June 4, 2026
Tracking structural variants in early breast cancer using a high-sensitivity ctDNA assay predicts relapse in the post-neoadjuvant setting: the multicenter ALIENOR trialC Blaye, F-C Bidard, L Hue, et al.
ESMO Open|May 22, 2021
HPV ctDNA detection of high-risk HPV types during chemoradiotherapy for locally advanced cervical cancerL Cabel, C Bonneau, A Bernard-Tessier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 14, 2025
Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trialK L Jhaveri, P Neven, M L Casalnuovo, et al.
Oncogene|January 7, 2023
Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access programD Bello Roufai, A Gonçalves, T De La Motte Rouge, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 7, 2025
Prognostic significance of early on-treatment evolution of circulating tumor DNA in advanced ER-positive/HER2-negative breast cancerA Mamann, Y Pradat, F C Bidard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2025
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapyE L Mayer, F-C Bidard, Y H Park, et al.
ESMO Open|April 10, 2026
Patient-reported outcomes and qualitative interviews in patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: results from the phase III EMBER-3 trialG Curigliano, J O'Shaughnessy, F-C Bidard, et al.
ESMO Open|November 26, 2025
PROMENADE: pembrolizumab for early ER-low/HER2-negative breast cancer, real-world French cohortF Cherifi, L Cabel, C Bousrih, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 9, 2017
Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumabJ-Y Pierga, F-C Bidard, A Autret, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 23, 2022
Current and future diagnostic and treatment strategies for patients with invasive lobular breast cancerK Van Baelen, T Geukens, M Maetens, et al.
Pageof 5